Cargando…
Overexpression of peptidase inhibitor 16 attenuates angiotensin II–induced cardiac fibrosis via regulating HDAC1 of cardiac fibroblasts
Cardiac hypertrophy and fibrosis are the major causes of heart failure due to non‐ischaemia heart disease. To date, no specific therapy exists for cardiac fibrosis due to the largely unknown mechanisms of disease and lack of applicable therapeutic targets. In this study, we aimed to explore the role...
Autores principales: | Deng, Mengqing, Yang, Shuo, Ji, Yue, Lu, Yan, Qiu, Ming, Sheng, Yanhui, Sun, Wei, Kong, Xiangqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205788/ https://www.ncbi.nlm.nih.gov/pubmed/32227584 http://dx.doi.org/10.1111/jcmm.15178 |
Ejemplares similares
-
Peptidase Inhibitor 16 Attenuates Left Ventricular Injury and Remodeling After Myocardial Infarction by Inhibiting the HDAC1‐Wnt3a‐β‐Catenin Signaling Axis
por: Wang, Luyang, et al.
Publicado: (2023) -
SGLT1 Knockdown Attenuates Cardiac Fibroblast Activation in Diabetic Cardiac Fibrosis
por: Lin, Hui, et al.
Publicado: (2021) -
Cardiac Fibrosis and Fibroblasts
por: Kurose, Hitoshi
Publicado: (2021) -
HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary
fibrosis
por: Lyu, Xing, et al.
Publicado: (2019) -
Sodium butyrate attenuates angiotensin II‐induced cardiac hypertrophy by inhibiting COX2/PGE2 pathway via a HDAC5/HDAC6‐dependent mechanism
por: Zhang, Linlin, et al.
Publicado: (2019)